From the Journals

Many ED visits may be preventable for NSCLC patients


 

FROM JCO ONCOLOGY PRACTICE

Leading cause is cancer

Overall, the leading cause of ED visits was NSCLC itself (54%). The patient’s cancer contributed to 61% of ED visits in the TKI group, 49% in the immunotherapy group, and 42% in the chemotherapy group.

Many ED visits were deemed unrelated to cancer or its therapies – 30% in the TKI group, 26% in the immunotherapy group, and 32% in the chemotherapy group.

Rule-out cases contributed to 7% of ED visits in the TKI group, 14% in the immunotherapy group, and 5% in the chemotherapy group.

Overall, 9% of ED visits were therapy related. The smallest proportion of these was observed in the TKI group (2%), which was significantly smaller than in the immunotherapy group (12%), a rate also significantly smaller than in the chemotherapy group (21%, P < .001).

Most unplanned ED visits did not lead to admissions (55%), were for complaints that began 2 or more days prior to presentation (53%), led to diagnostics or therapeutics that could have been administered in an outpatient setting (48%), and were during business hours (52%).

As a result, 24% of visits were classified as preventable, and 10% were deemed unnecessary.

Preventive strategies

“Our study suggests that TKIs lead to fewer emergency room visits than immunotherapy and chemotherapy,” Dr. Shah said in an interview.

“Overall, this may not necessarily change which therapy we prescribe,” he added, “as TKI therapy is often first line for patients with targeted mutations. However, recognizing that those on chemotherapy or immunotherapy are at higher risk for emergency room visits, we may target preventative strategies, for example, nursing phone calls, telemonitoring of symptoms, and frequent video visits toward this high-risk population.”

Dr. Shah and Dr. Neal said it’s “reassuring” that TKIs and immunotherapy are small drivers of unplanned hospital care. However, they also said efforts aimed at reducing chemotherapy-related ED visits are warranted.

The authors speculated that early intervention, extension of ambulatory care, and patient education about outpatient avenues of care could eliminate a significant proportion (at least 20%) of unplanned ED visits by NSCLC patients.

There was no specific funding for this study. Dr. Shah disclosed no conflicts of interest. Dr. Neal disclosed relationships with many companies, including this news organization.

Pages

Recommended Reading

How should we evaluate the benefit of immunotherapy combinations?
MDedge Hematology and Oncology
Rechallenge ‘reasonable’ for some with small-cell lung cancer
MDedge Hematology and Oncology
Patients with lung and blood cancers most vulnerable to COVID-19
MDedge Hematology and Oncology
Most common cancer diagnosis globally: Breast surpasses lung
MDedge Hematology and Oncology
COVID-19 vaccines and cancer patients: 4 things to know
MDedge Hematology and Oncology
FDA OKs osimertinib as first adjuvant drug for NSCLC
MDedge Hematology and Oncology
Two different radiation boost strategies reduce local failures in NSCLC
MDedge Hematology and Oncology
‘Contrary’ to wide belief, abscopal effect is rare in cancer
MDedge Hematology and Oncology
U.S. cancer death rates drop for second year in a row
MDedge Hematology and Oncology
Case study: Maternal cervical cancer linked to neonate lung cancer
MDedge Hematology and Oncology